CN115088833A - Functional food for preventing and/or treating intestinal injury of tumor patient - Google Patents
Functional food for preventing and/or treating intestinal injury of tumor patient Download PDFInfo
- Publication number
- CN115088833A CN115088833A CN202210553684.2A CN202210553684A CN115088833A CN 115088833 A CN115088833 A CN 115088833A CN 202210553684 A CN202210553684 A CN 202210553684A CN 115088833 A CN115088833 A CN 115088833A
- Authority
- CN
- China
- Prior art keywords
- tumor
- patients
- vitamin
- preventing
- functional
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 58
- 235000013376 functional food Nutrition 0.000 title claims abstract description 10
- 208000037817 intestinal injury Diseases 0.000 title abstract description 11
- 239000000843 powder Substances 0.000 claims abstract description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 9
- 229930003270 Vitamin B Natural products 0.000 claims abstract description 8
- 235000019156 vitamin B Nutrition 0.000 claims abstract description 8
- 239000011720 vitamin B Substances 0.000 claims abstract description 8
- 229920001353 Dextrin Polymers 0.000 claims abstract description 5
- 239000004375 Dextrin Substances 0.000 claims abstract description 5
- 235000019425 dextrin Nutrition 0.000 claims abstract description 5
- 229940089161 ginsenoside Drugs 0.000 claims abstract description 5
- 229930182494 ginsenoside Natural products 0.000 claims abstract description 5
- 239000011780 sodium chloride Substances 0.000 claims abstract description 5
- OAVRWNUUOUXDFH-UHFFFAOYSA-H 2-hydroxypropane-1,2,3-tricarboxylate;manganese(2+) Chemical compound [Mn+2].[Mn+2].[Mn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O OAVRWNUUOUXDFH-UHFFFAOYSA-H 0.000 claims abstract description 4
- 229920001202 Inulin Polymers 0.000 claims abstract description 4
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 4
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 4
- HLCFGWHYROZGBI-JJKGCWMISA-M Potassium gluconate Chemical compound [K+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O HLCFGWHYROZGBI-JJKGCWMISA-M 0.000 claims abstract description 4
- 235000019484 Rapeseed oil Nutrition 0.000 claims abstract description 4
- 108010073771 Soybean Proteins Proteins 0.000 claims abstract description 4
- 229930003316 Vitamin D Natural products 0.000 claims abstract description 4
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 4
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 4
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 4
- 240000008042 Zea mays Species 0.000 claims abstract description 4
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims abstract description 4
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 4
- 235000019864 coconut oil Nutrition 0.000 claims abstract description 4
- 239000003240 coconut oil Substances 0.000 claims abstract description 4
- 235000005822 corn Nutrition 0.000 claims abstract description 4
- 235000013312 flour Nutrition 0.000 claims abstract description 4
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims abstract description 4
- 229940107187 fructooligosaccharide Drugs 0.000 claims abstract description 4
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 4
- 229940029339 inulin Drugs 0.000 claims abstract description 4
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 4
- 239000011564 manganese citrate Substances 0.000 claims abstract description 4
- 235000014872 manganese citrate Nutrition 0.000 claims abstract description 4
- 229940097206 manganese citrate Drugs 0.000 claims abstract description 4
- 239000004224 potassium gluconate Substances 0.000 claims abstract description 4
- 235000013926 potassium gluconate Nutrition 0.000 claims abstract description 4
- 229960003189 potassium gluconate Drugs 0.000 claims abstract description 4
- 235000019710 soybean protein Nutrition 0.000 claims abstract description 4
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 claims abstract description 4
- 235000019166 vitamin D Nutrition 0.000 claims abstract description 4
- 239000011710 vitamin D Substances 0.000 claims abstract description 4
- 150000003710 vitamin D derivatives Chemical class 0.000 claims abstract description 4
- 229940046008 vitamin d Drugs 0.000 claims abstract description 4
- 235000021119 whey protein Nutrition 0.000 claims abstract description 4
- 239000011746 zinc citrate Substances 0.000 claims abstract description 4
- 235000006076 zinc citrate Nutrition 0.000 claims abstract description 4
- 229940068475 zinc citrate Drugs 0.000 claims abstract description 4
- 238000002360 preparation method Methods 0.000 claims description 6
- 230000003903 intestinal lesions Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 235000013305 food Nutrition 0.000 abstract description 16
- 239000003814 drug Substances 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 5
- 235000015097 nutrients Nutrition 0.000 abstract description 4
- 238000011160 research Methods 0.000 abstract description 4
- 230000036528 appetite Effects 0.000 abstract description 3
- 235000019789 appetite Nutrition 0.000 abstract description 3
- 230000003871 intestinal function Effects 0.000 abstract description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 16
- 229960002949 fluorouracil Drugs 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 13
- 238000000034 method Methods 0.000 description 7
- 235000016709 nutrition Nutrition 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 230000010100 anticoagulation Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 235000000824 malnutrition Nutrition 0.000 description 2
- 230000001071 malnutrition Effects 0.000 description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 description 2
- 235000003715 nutritional status Nutrition 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010012741 Diarrhoea haemorrhagic Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- JSRLJPSBLDHEIO-SHYZEUOFSA-N dUMP Chemical compound O1[C@H](COP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 JSRLJPSBLDHEIO-SHYZEUOFSA-N 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- JJJFUHOGVZWXNQ-UHFFFAOYSA-N enbucrilate Chemical group CCCCOC(=O)C(=C)C#N JJJFUHOGVZWXNQ-UHFFFAOYSA-N 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 235000020802 micronutrient deficiency Nutrition 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 235000021049 nutrient content Nutrition 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003106 tissue adhesive Substances 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pediatric Medicine (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses a functional food for preventing and/or treating intestinal injury of a tumor patient. The functional food contains, per 100 g: 8-9g of whey protein powder, 5-7g of soybean protein isolate, 6-8g of rapeseed oil powder, 4-7g of coconut oil powder, 20-25g of fructo-oligosaccharide, 25-30g of maltodextrin, 25-28g of resistant dextrin, 0.15-0.4 g of inulin, 0.1-0.3g of potassium gluconate, 60.004-0.006 g of vitamin B, 3100-115 IU of vitamin D, 10.0025-0.004 g of vitamin B, 0.002-0.0035g of zinc citrate, 0.0028-0.004g of manganese citrate, 0.002-0.005g of sodium chloride, 0.3-0.5g of corn flour and 5-8g of ginsenoside. The functional formula food prepared by the invention is used for preventing and/or treating intestinal injury of tumor patients through a series of experimental researches, and the results show that the functional formula food obviously improves the appetite of the patients, promotes the intake of nutrient components of the patients, has obvious protection effect on the intestinal function, and provides a new idea for the medicine research of the tumor patients.
Description
Technical Field
The invention belongs to the technical field of functional formula foods, and particularly relates to a functional food for preventing and/or treating intestinal injury of a tumor patient.
Background
The common state of nutrition-metabolism imbalance of malignant tumor patients comprises serious insufficient calorie intake, increased demand caused by insufficient protein intake, muscular atrophy, increased demand for organism tissue repair, intestinal flora imbalance with flora diversity changed into prominent appearance, micronutrient deficiency and electrolyte disorder, and high blood coagulation state of organism. The tumor food plays a role in the auxiliary treatment of tumor metabolic syndromes such as intestinal flora imbalance, poor clinical manifestations of nutrient deficiency, cancerous cachexia, hyperglycemia, insulin resistance, hyperlipidemia and the like, high blood coagulation state and radiation enteritis of a patient, and the auxiliary maintenance and repair of intestinal dysfunction.
Especially, the malnutrition caused by the tumor of the chronic disease is the root cause of the disease deterioration, slow recovery and pain of the patient. In order to meet the special requirements of tumor patients on nutrients or diet caused by limited eating, metabolic disturbance and digestive absorption disorder, the formula food prepared and processed can be used for correcting the subsequent adverse reactions brought by cancerous malnutrition. And the conventional chemotherapeutic drug 5-FU for tumors is converted into 5-fluorouracil deoxynucleotide (5F-dUMP) in cells during the treatment process, so that deoxythymidylate synthase is inhibited, and the methylation of deoxyuridylate (dUMP) is prevented from being converted into deoxythymidylate (dTMP), thereby influencing the synthesis of DNA. Literature statistics shows that about 50% -80% of patients suffer from intestinal inflammation and other diseases in the treatment process, and have gastrointestinal reactions, such as anorexia, nausea, vomiting, stomatitis, gastritis and diarrhea, and even bloody diarrhea in severe cases. Therefore, the nutritional status of patients needs to be closely concerned, the nutritional status is evaluated and screened according to the time line, and the nutritional treatment and the auxiliary administration degree are selected according to the disease stage of tumor patients and different positions of tumors. The nutrition therapy is equal to the antitumor therapy such as surgery, radiotherapy, drug therapy and the like, and focuses on nutrition metabolism therapy, namely relieving the pain of patients, saving the cost and improving the life quality. At present, nutrient preparations aiming at gastrointestinal tract diseases such as intestinal inflammation of tumor patients in the market have single nutrient content and rare varieties.
Disclosure of Invention
The invention aims to provide a functional food for preventing and/or treating intestinal injury of a tumor patient.
In order to achieve the purpose, the invention adopts the following technical scheme:
a functional food comprises, per 100 g: 8-9g of whey protein powder, 5-7g of soybean protein isolate, 6-8g of rapeseed oil powder, 4-7g of coconut oil powder, 20-25g of fructo-oligosaccharide, 25-30g of maltodextrin, 25-28g of resistant dextrin, 0.15-0.4 g of inulin, 0.1-0.3g of potassium gluconate, 60.004-0.006 g of vitamin B, 3100-115 IU of vitamin D, 10.0025-0.004 g of vitamin B, 0.002-0.0035g of zinc citrate, 0.0028-0.004g of manganese citrate, 0.002-0.005g of sodium chloride, 0.3-0.5g of corn flour and 5-8g of ginsenoside.
The functional food is applied to preparing products for preventing and/or treating intestinal injuries of tumor patients.
The functional formula food is applied to the aspect of preparing the food preparation for preventing and/or treating the intestinal injury of the tumor patients, and is used for improving the intestinal injury of the patients, improving the appetite and nutrient absorption of the patients and further enhancing the subsequent tumor treatment effect, so that a new source is provided for preparing the food preparation for preventing and/or treating the intestinal injury of the tumor patients, and a new medicinal value of the functional formula food is developed.
Drawings
FIG. 1 is a statistical result of tumor volumes of groups of mice 15 days after administration.
FIG. 2 is a photograph of tumor volumes of groups of mice 15 days after administration.
Detailed Description
The invention is described in further detail below with reference to the figures and the examples, but the invention should not be construed as being limited thereto. Modifications or substitutions to methods, procedures, or conditions of the invention may be made without departing from the spirit and scope of the invention. The experimental methods and reagents of the formulations not specified in the examples were carried out according to the conventional conditions in the art.
Example 1
1. Reagents and animals:
functional formula food: every 100g of formula food (10-15% of amino acid type and short peptide type protein, 10-16% of fat portion composed of long chain triglyceride LCT and medium chain triglyceride MCT, 70-73% of carbohydrate mainly containing dextrin and food starch with certain components, and simultaneously adding various vitamins, minerals and trace elements necessary for human body, 5-8% of ginsenoside extracted from ginseng medicine): 8.5g of whey protein powder, 6g of soybean protein isolate, 7g of rapeseed oil powder, 6g of coconut oil powder, 22g of fructo-oligosaccharide, 25g of maltodextrin, 25g of resistant dextrin, 0.3g of inulin, 0.2g of potassium gluconate, 60.005g of vitamin B, 3110 IU of vitamin D, 10.003g of vitamin B, 0.003g of zinc citrate, 0.003g of manganese citrate, 0.004g of sodium chloride, 0.4g of corn flour and 6g of ginsenoside.
Experimental animals: adult male C57BL/6 mice for experiments are 8-10 weeks old and 25-30g in weight, are purchased in Shanghai laboratory animal center, SPF level animals are bred in Nantong university laboratory animal center, the laboratory animal temperature is 20-26 ℃ (the daily temperature difference is less than or equal to 4 ℃), the humidity is 40-70%, and the lighting is 12 h: alternating light and shade for 12 h.
2. The experimental contents are as follows:
animal grouping: tumor model group (A), tumor model +5-FU group (B), tumor model +5-FU + functional formula group (C), and tumor model +5-FU + Yibukang positive control group (D). The mice were divided into 4 groups of 6 mice each, and assigned randomly according to group.
The packet design is shown in table 1.
TABLE 1
3. The test method comprises the following steps:
the operation is as follows:
(1) the method for establishing the mouse tumor model comprises the following steps: taking CT26.WT fine powder in logarithmic growth phaseThe cells were prepared as single cell suspensions with a cell density of 1X 10 10 One cell per liter, 0.1mL, i.e., 1X 10 seeded cells 6 And inoculating the strain to the right axilla of inbred BALB/c mice. After 10 days, solid tumors with a diameter of about 1cm grew out. Establishing a mouse CT26.WT colon cancer orthotopic transplantation tumor model: firstly, killing subcutaneous tumor-bearing mice, disinfecting skin, stripping subcutaneous tumor, immediately immersing into physiological saline containing penicillin and streptomycin respectively 100U/mL, removing peripheral connective tissue, taking fish meat-shaped tissue with vigorous tumor growth, and cutting into pieces of 1mm 3 The tumor mass of the size is reserved. C57BL/6 mice were weighed respectively, anesthetized by 2% sodium pentobarbital 100mg/kg right intraperitoneal injection, and then taken out in supine position, the four limbs were fixed, and the abdominal operative field was disinfected with ethanol. The incision of the left lower abdomen is about 1cm, the skin and subcutaneous layer on the right side of the incision are slightly dissociated, the blind colon is exposed, the blind colon is dragged out to the subcutaneous part, and the abdominal cavity on the upper edge and the lower edge of the blind colon is closed. Gently scraping off a little serosa at the junction of the blind colon by using a No. 4 needle, leaking blood, selecting 1 prepared tumor mass, pasting the tumor mass on the scratched part, bonding the tumor mass by using Histoacryl medical tissue glue, bringing the external intestinal segment back into the abdomen, and suturing the abdominal wall. The whole process follows the principle of aseptic operation. After waking, the mice are placed in an SPF animal room for conventional breeding.
(2) Mice successfully modeled are randomly selected and divided into four groups, each group comprises 6 mice, and the mice are divided into a tumor model group, a tumor model +5-FU + functional formula group and a tumor model +5-FU + Yibukang positive control group. The three groups were intraperitoneally injected with fluorouracil solution (30mg kg) every two days -1 ) The tumor model group was administered an equal volume of saline by gavage daily during the test period, and this operation was continued for 15 days.
(3) The medicine is taken the next day after the model is successfully made, the tumor model +5-FU + functional formula group, the tumor model +5-FU + Yibukang positive control group are given the functional formula food and the Yibukang nutrient preparation with the same dose according to the same calorie, and the other two groups are given the feed with the same calorie.
4. Observation index
General state observation: observation time and frequency: observing for 1 time every day at fixed time before and after administration; and (4) observing results: the overall condition of the test animals during the dosing period.
Treating for 4 weeks, observing the change of mouse morphology and tumor volume, detecting the change of plasma nutrition index, inflammation index, immunity index, nitrogen balance, blood cell count and plasma protein.
(1) Change in mouse morphology and tumor volume
Mice were observed daily for appearance, including gross color, food and water intake, mental status, and activity. At the same time, the body weight of the mice was recorded every 7 days; measuring the size of the tumor every 3 days, and calculating the tumor
Volume.
Tumor volume (mm) is length (mm) x width (mm) x height (mm)/2.
The next day after dosing, mice were sacrificed by dislocation of the cervical vertebrae, and tumor masses were removed and weighed.
(2) Nutritional index
After fasting for 12 hours at 1, 2, 3 and 4w respectively after successful molding, taking blood from heart, adding 1% EDTA disodium solution for anticoagulation, centrifuging at 3000r/min for 5min, taking supernatant, and measuring Total Protein (TP) and Albumin (Albumin, Alb) concentration of plasma by using a full-automatic biochemical analyzer.
(3) Index of inflammation
After fasting for 12 hours at 1, 2, 3 and 4w after successful molding, respectively, taking blood from heart, adding 1% EDTA disodium solution for anticoagulation, centrifuging at 3000r/min for 5min, taking supernatant, and performing ELISA
The kit is used for measuring the levels of Tumor Necrosis Factor (Tumor Necrosis Factor, TNF-alpha) and Interleukin-2 (Interleukin-2, IL-2) in mice.
(4) Index of immunity
After fasting for 12 hours at 1, 2, 3 and 4w after successful molding, respectively, taking blood from heart, adding 1% EDTA disodium solution for anticoagulation, centrifuging at 3000r/min for 5min, taking supernatant, and performing ELISA
The kit measures the levels of mouse Ig G, Ig A and Ig M.
5. Statistical analysis
Test data are expressed as Mean ± SD, and differences between groups were compared using one-way ANOVA test (M-W method). Statistical analysis showed that P <0.05 was considered significantly different, and P <0.01 and P <0.001 were considered very significantly different.
6. The experimental results are as follows:
as shown in fig. 1 and 2, fifteen days after administration, compared to the tumor model group, the tumor model +5-FU (# # P <0.001), the tumor model +5-FU + functional formula group (# # P <0.0001), and the tumor model +5-FU + Yibukang positive control group (# # P <0.001) showed that the tumor volume was significantly reduced in the group receiving the medication. Meanwhile, the tumor model +5-FU + functional formula group is compared with the tumor model +5-FU group (P <0.01) and the tumor model +5-FU + Yibukang positive control group (P <0.05), and the functional formula can effectively reduce the tumor volume and has obviously better effect than the Yibukang nutritional preparation.
The functional formula food prepared by the invention is used for preventing and/or series experimental researches on intestinal injuries of tumor patients, and results show that the functional formula food remarkably improves the appetite of the patients, promotes the intake of nutritional ingredients of the patients, has obvious protection effect on the intestinal functions, and provides a new idea for the medicine research of the tumor patients.
Claims (2)
1. A functional food characterized by: each 100g contains: 8-9g of whey protein powder, 5-7g of soybean protein isolate, 6-8g of rapeseed oil powder, 4-7g of coconut oil powder, 20-25g of fructo-oligosaccharide, 25-30g of maltodextrin, 25-28g of resistant dextrin, 0.15-0.4 g of inulin, 0.1-0.3g of potassium gluconate, 60.004-0.006 g of vitamin B, 3100-115 IU of vitamin D, 10.0025-0.004 g of vitamin B, 0.002-0.0035g of zinc citrate, 0.0028-0.004g of manganese citrate, 0.002-0.005g of sodium chloride, 0.3-0.5g of corn flour and 5-8g of ginsenoside.
2. Use of the functional food according to claim 1 for the preparation of a product for the prevention and/or treatment of intestinal lesions in patients with tumors.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210553684.2A CN115088833A (en) | 2022-05-20 | 2022-05-20 | Functional food for preventing and/or treating intestinal injury of tumor patient |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210553684.2A CN115088833A (en) | 2022-05-20 | 2022-05-20 | Functional food for preventing and/or treating intestinal injury of tumor patient |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115088833A true CN115088833A (en) | 2022-09-23 |
Family
ID=83289860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210553684.2A Pending CN115088833A (en) | 2022-05-20 | 2022-05-20 | Functional food for preventing and/or treating intestinal injury of tumor patient |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115088833A (en) |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040101593A1 (en) * | 2001-03-02 | 2004-05-27 | Nobutaka Suzuki | Preventives or remedies for tumor of human papillomaviral disease |
| KR20100013648A (en) * | 2008-07-31 | 2010-02-10 | 주식회사 진생사이언스 | A composition comprising ginsenosides isolated from the extract of processed ginseng for preventing and treating thrombotic disease |
| CN103330215A (en) * | 2013-07-11 | 2013-10-02 | 西安力邦临床营养有限公司 | Nutrition formula food applicable to tumor patient |
| WO2014168447A1 (en) * | 2013-04-11 | 2014-10-16 | 한국한의학연구원 | Pharmaceutical composition and functional health food for preventing or treating cancer containing natural extract as active ingredient |
| CN105816469A (en) * | 2015-01-06 | 2016-08-03 | 富力 | Application of 20(R)-ginsenoside Rg3 in preparation of medicine or health product for treating osteoporosis and medicine thereof |
| CN106581022A (en) * | 2016-12-04 | 2017-04-26 | 西北大学 | Application of ginsenoside Rk1 to preparation of anti-tumor drugs |
| US20170143748A1 (en) * | 2014-06-16 | 2017-05-25 | Xueyong WANG | Anti-tumor pharmaceutical application of pentacyclic triterpene saponin compounds of szechuan melandium root |
| CN111759853A (en) * | 2020-07-17 | 2020-10-13 | 陕西巨子生物技术有限公司 | Pharmaceutical composition and application thereof |
| WO2021197372A1 (en) * | 2020-03-31 | 2021-10-07 | 陕西巨子生物技术有限公司 | Anti-tumor composition containing rare ginsenosides rk2, ck, and ppt |
| CN113575934A (en) * | 2021-08-02 | 2021-11-02 | 山东哈维药业有限公司 | Total-nutrient compound protein powder for tumor patients |
| CN115039876A (en) * | 2022-05-20 | 2022-09-13 | 南通大学 | A functional food for preventing and/or treating leukodystrophy |
-
2022
- 2022-05-20 CN CN202210553684.2A patent/CN115088833A/en active Pending
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040101593A1 (en) * | 2001-03-02 | 2004-05-27 | Nobutaka Suzuki | Preventives or remedies for tumor of human papillomaviral disease |
| KR20100013648A (en) * | 2008-07-31 | 2010-02-10 | 주식회사 진생사이언스 | A composition comprising ginsenosides isolated from the extract of processed ginseng for preventing and treating thrombotic disease |
| WO2014168447A1 (en) * | 2013-04-11 | 2014-10-16 | 한국한의학연구원 | Pharmaceutical composition and functional health food for preventing or treating cancer containing natural extract as active ingredient |
| CN103330215A (en) * | 2013-07-11 | 2013-10-02 | 西安力邦临床营养有限公司 | Nutrition formula food applicable to tumor patient |
| US20170143748A1 (en) * | 2014-06-16 | 2017-05-25 | Xueyong WANG | Anti-tumor pharmaceutical application of pentacyclic triterpene saponin compounds of szechuan melandium root |
| CN105816469A (en) * | 2015-01-06 | 2016-08-03 | 富力 | Application of 20(R)-ginsenoside Rg3 in preparation of medicine or health product for treating osteoporosis and medicine thereof |
| CN106581022A (en) * | 2016-12-04 | 2017-04-26 | 西北大学 | Application of ginsenoside Rk1 to preparation of anti-tumor drugs |
| WO2021197372A1 (en) * | 2020-03-31 | 2021-10-07 | 陕西巨子生物技术有限公司 | Anti-tumor composition containing rare ginsenosides rk2, ck, and ppt |
| CN111759853A (en) * | 2020-07-17 | 2020-10-13 | 陕西巨子生物技术有限公司 | Pharmaceutical composition and application thereof |
| CN113575934A (en) * | 2021-08-02 | 2021-11-02 | 山东哈维药业有限公司 | Total-nutrient compound protein powder for tumor patients |
| CN115039876A (en) * | 2022-05-20 | 2022-09-13 | 南通大学 | A functional food for preventing and/or treating leukodystrophy |
Non-Patent Citations (1)
| Title |
|---|
| 聂世鸿;臧健;曹丹;刘太国;易成;: "人参皂苷Rg3对小鼠大肠癌细胞的抗肿瘤活性研究", 华西医学, no. 03, pages 411 - 416 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104366480A (en) | Lipid-lowering and weight-reducing nutritional meal powder and preparation method thereof | |
| CN111011691A (en) | High-protein high-fiber solid beverage | |
| HU206987B (en) | Process for producing oral pharmaceutical compositions comprising alpha- or beta-interferon, suitable for reducing side effects of cancer therapy | |
| CN1759877A (en) | Composition of medication for treating anemia, and application | |
| WO2011047518A1 (en) | Enteral nutrition comprising marine bioactive polysaccharide, preparation method and use thereof | |
| CN101544686A (en) | Application of glycopeptide mixture in preparing adjuvant therapy medicaments of tumor and health food | |
| CN102048225B (en) | Red-date health protection beverage capable of improving growing development | |
| CN101433267B (en) | Additive agent for chicken feed | |
| CN106418545A (en) | Functional food with balanced nutrients | |
| CN107279978A (en) | A kind of special medicine purposes formula food suitable for tumour patient | |
| CN105124347A (en) | Moringa oleifera blood-glucose-reducing composition and preparation method thereof | |
| CN110150654A (en) | A kind of special medicine purposes formula food for tumor patient | |
| CN1101700C (en) | Polypeptide oral liquor | |
| CN115088833A (en) | Functional food for preventing and/or treating intestinal injury of tumor patient | |
| JP2002209553A (en) | Carcinostatic healthy food and additive for healthy food | |
| CN111493221A (en) | Traditional Chinese medicine feed additive for improving animal immunity and preparation method thereof | |
| CN113133531A (en) | Compound protein supplement and preparation method thereof | |
| CN105432972A (en) | Selenium-rich feed additive for weever | |
| CN101797049B (en) | Nutrient eight-treasure soup formula and preparation process thereof | |
| CN107549692A (en) | A kind of ocean polypeptide spy's dietary seafood for patients undergoing chemotherapy post-operative recovery | |
| CN108619483B (en) | A biological protein extracted from pupa Bombycis for lowering blood sugar and balancing dietary nutrition | |
| CN106035686A (en) | Super chenopodium quinoa willd health-preservation plant milk | |
| CN104921100A (en) | Non-total nutrient formula food for recuperating from chloasma | |
| US7998500B2 (en) | Nutritional supplement for women | |
| CN110638041A (en) | Food for improving blood sugar and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |